.jpg "GlycoMimetics (NASDAQ: GLYC)")
Roth Capital analyst Jotin Marango maintained a Buy rating on GlycoMimetics (GLYC) today and set a price target of $35. The company’s shares closed on Friday at $13.25.
According to TipRanks.com, Marango is a 1-star analyst with an average return of -3.3% and a 29.3% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GlycoMimetics with a $24 average price target, implying an 81.1% upside from current levels. In a report issued on October 28, Cowen & Co. also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.05 and a one-year low of $10.56. Currently, GlycoMimetics has an average volume of 275.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates.
